Indaptus Therapeutics Terminates Merger with 03 Life Sciences

Ticker: INDP · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1857044

Indaptus Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyIndaptus Therapeutics, INC. (INDP)
Form Type8-K
Filed DateOct 22, 2024
Risk Levelmedium
Pages4
Reading Time5 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: merger-termination, corporate-events

TL;DR

Indaptus Therapeutics just killed its merger with 03 Life Sciences, effective immediately. Deal's off.

AI Summary

On October 17, 2024, Indaptus Therapeutics, Inc. announced the termination of its previously announced merger agreement with 03 Life Sciences, Inc. The termination was effective immediately. No specific reasons for the termination were disclosed in the filing.

Why It Matters

The termination of this merger agreement could significantly impact the strategic direction and future operations of Indaptus Therapeutics, potentially affecting its stock value and investor confidence.

Risk Assessment

Risk Level: medium — The termination of a merger agreement can introduce uncertainty regarding the company's future strategy and financial stability, potentially leading to increased volatility.

Key Players & Entities

FAQ

What was the effective date of the merger agreement termination?

The termination was effective immediately as of October 17, 2024.

Which companies were involved in the terminated merger agreement?

Indaptus Therapeutics, Inc. and 03 Life Sciences, Inc. were involved in the terminated merger agreement.

What is the filing form used for this announcement?

The filing form used is a Form 8-K.

What is the principal executive office address for Indaptus Therapeutics, Inc.?

The address is 3 Columbus Circle, 15th Floor, New York, New York 10019.

What is the IRS Employer Identification Number for Indaptus Therapeutics, Inc.?

The IRS Employer Identification Number is 86-3158720.

Filing Stats: 1,214 words · 5 min read · ~4 pages · Grade level 19.9 · Accepted 2024-10-22 08:05:15

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 22, 2024 INDAPTUS THERAPEUTICS, INC. By: /s/ Nir Sassi Name: Nir Sassi Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing